

<b>UTILITY PATENT APPLICATION TRANSMITTAL (Under 37 C.F.R. §1.53(b))</b>		Docket No.: ECV-5608 Title: TREATMENT OF BIOPROSTHETIC TISSUES TO MITIGATE POST IMPLANTATION CALCIFICATION Express Mail Label No.: EL599141892US	Page 1 of 2
<b>APPLICATION ELEMENTS</b>			
<b>INVENTOR(S):</b> SOPHIE M. CARPENTIER AND ALAIN F. CARPENTIER			
<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Applications Washington D.C. 20231			
<b>1.</b> <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)			
<b>2.</b> <input checked="" type="checkbox"/> Specification, including claims and abstract [Total Pages <b>33</b> ]			
<b>3.</b> <input checked="" type="checkbox"/> Claims [Total No. <b>92</b> ]			
<b>4.</b> <input checked="" type="checkbox"/> Drawing(s) (35 USC §113) [Total Sheets <b>2</b> ] (Figs.1 & 2)			
<b>5.</b> <input checked="" type="checkbox"/> Signed Declaration [Total Pages <b>2</b> ]			
a. <input checked="" type="checkbox"/> Newly executed (original or copy)			
b. <input type="checkbox"/> Copy from a prior application (37 CFR §1.63(d))			
<b>(Note Box 5 below)</b>			
<b>6.</b> <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u>  Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)			
<b>7.</b> <input type="checkbox"/> Microfiche Computer Program			
<b>8.</b> <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission			
<b>9.</b> <input checked="" type="checkbox"/> Assignment Papers with recordation sheet (2 pages)			
<b>10.</b> <input type="checkbox"/> 37 CFR §3.73(b) Statement <input type="checkbox"/> Power of Attorney			
<b>11.</b> <input type="checkbox"/> English Translation Document			
<b>18.</b> If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:  <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: _____ / _____			
<b>19.</b> The present application claims priority under 35 USC § 119 to U.S. Provisional Application No. _____, filed _____.			

UTILITY PATENT  
APPLICATION TRANSMITTAL  
(Under 37 C.F.R. §1.53(b))

Docket No.: ECV-5608  
Page 2 of 2  
Title: TREATMENT OF BIOPROSTHETIC TISSUES TO  
MITIGATE POST IMPLANTATION CALCIFICATION  
Express Mail Label No.: EL599141892US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	92-20=	72	X \$18 =	\$1296
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	4 -3=	1	\$84 =	\$84
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 280 =	\$
				BASIC FEE (37 CFR §1.16(a))	\$740
				TOTAL =	\$2120

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 501225 (Docket ~~501225~~ 5608)  
(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a.  Fees required under 37 CFR §1.16
- b.  Fees required under 37 CFR §1.17
- c.  Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	Debra D. Condino, Reg. No. 31,007
SIGNATURE	
DATE	January 3, 2002

CORRESPONDENCE ADDRESS

Edwards Lifesciences LLC

Law Dept.

One Edwards Way

Irvine, California 92614

Telephone: (949) 250-6803 Fax: (949) 250-6850

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail No. EL599141892US in an envelope addressed to Assistant Commissioner for Patents, 2900 Crystal Drive, Arlington, VA 22202-3513 on Jan 3, 2002

By: 